Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors
ImmunOs Therapeutics AG
This study will be conducted in 3 parts. Part A (Phase 1a, monotherapy and combination therapy dose escalation): IOS-1002 alone and IOS-1002 plus PD-1 mAb in people with advanced solid cancers. Part B (Phase 1b, monotherapy cohort expansion): IOS-1002 alone in people with advanced solid cancers. Part C (Phase 1b, combination therapy cohort expansion): IOS-1002 plus PD-1 mAb in people with advanced solid cancers